Completed PHASE3 INTERVENTIONAL 3-arm NCT00745108

Tibolone Endometrium Study (Study 32972)(P06470) (THEBES)

A Multinational, Multicenter, Randomized, Double-blind, Parallel Group, Active Controlled, Comparative Trial, to Assess the Endometrial Histological Profile Following Treatment With Tibolone (Org OD14) Versus Conjugated Estrogen (CE) Plus Medroxyprogesterone Acetate (MPA) in Postmenopausal Women

Sponsor: Organon and Co

Conditions Postmenopausal Women

Interventions CE/MPA Tibolone 2.5 mg tibolone

Updated 9 times since 2017 Last updated: Feb 2, 2022 Started: Oct 1, 2001 Primary completion: Jul 21, 2005 Completion: Jul 21, 2005

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Postmenopausal Women, this trial is completed. The trial is conducted by Organon and Co and has accumulated 9 data snapshots since 2001. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

9 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Mar 2022 — Jul 2024 [monthly]

Completed PHASE3
Jan 2021 — Mar 2022 [monthly]

Completed PHASE3
Dec 2019 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 4 earlier versions

Jun 2018 — Dec 2019 [monthly]

Completed PHASE3
May 2017 — Jun 2018 [monthly]

Completed PHASE3
Feb 2017 — May 2017 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Oct 2001

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Organon and Co

Data source: Organon and Co

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.